A 68-year-old man presented to our hospital with chest pain and cardiac pulmonary arrest (CPA). Two weeks previously, he had experienced atrial fibrillation which had been treated by bisoprolol, a β1 selective blocker. He had already stopped smoking ten years previously. Although he had hypertension, he had no other coronary risk factors (including dyslipidemia, diabetes mellitus, or a family history of cardiac disease). After resuscitation, ECG showed ST-segment elevation in the aVR lead with diffuse ST-segment depression. Coronary angiography revealed diffuse severe narrowing in the left anterior descending, left circumflex ([Picture 1](#g001){ref-type="fig"}), and right coronary arteries ([Picture 2](#g002){ref-type="fig"}). However, no significant organic stenosis was observed after the intracoronary administration of nitrate ([Picture 3](#g003){ref-type="fig"}, [4](#g004){ref-type="fig"}). He was diagnosed with CPA due to multi-vessel coronary artery spasm. Beta-blocker treatment was discontinued and treatment with calcium antagonist and nitrate were started. Two years later, the patient remains free of symptoms and no other events have occurred.
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Beta-blockers can theoretically cause coronary vasoconstriction because the activation of the β2-adrenergic receptors can cause vascular smooth muscle dilatation; however, this effect tends to be outweighed by the vasoconstricting α1-receptors ([@B1],[@B2]). Physicians should therefore exercise caution when prescribing beta-blockers to patients with chest pain.
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